Stockscreener 앱 받기
36.64
2.77%
-1.045
시간 외 거래:
36.64
전일 마감가:
$37.69
열려 있는:
$37.2
하루 거래량:
534.30K
Relative Volume:
0.80
시가총액:
$1.69B
수익:
-
순이익/손실:
$-146.66M
주가수익비율:
-13.30
EPS:
-2.7541
순현금흐름:
$-133.21M
1주 성능:
-7.19%
1개월 성능:
-3.02%
6개월 성능:
-18.85%
1년 성능:
-20.97%
1일 변동 폭
$35.71
$37.20
1주일 범위
$35.71
$40.08
52주 변동 폭
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
APGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
36.64 | 2.30B | 0 | -146.66M | -133.21M | -2.7541 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire
4,824 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by BNP Paribas Financial Markets - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Has $5.90 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
(APGE) Investment Analysis and Advice - news.stocktradersdaily.com
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock By Investing.com - Investing.com India
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock - Investing.com
D. E. Shaw & Co. Inc. Has $445,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $94.60 - Defense World
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet - MSN
How To Trade (APGE) - news.stocktradersdaily.com
Northern Trust Corp Grows Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for APGE - Defense World
Q1 Earnings Forecast for APGE Issued By Wedbush - Defense World
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma - marketscreener.com
Apogee Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class (APGE) - Seeking Alpha
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target By Investing.com - Investing.com India
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target - Investing.com
Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Benzinga
Apogee Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Apogee Therapeutics reports positive results from asthma treatment trial - Seeking Alpha
Apogee Therapeutics (APGE) Reports Promising Phase 1b Trial Resu - GuruFocus
Apogee (APGE) Sets Sights on Transformative Achievements in 2025 - GuruFocus
Apogee Therapeutics Q1 Loss Widens - marketscreener.com
Apogee Therapeutics Reports Positive Phase 1b Trial Results - TipRanks
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $55.3M, vs. FactSet Est of $72.3M Loss - marketscreener.com
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - The Manila Times
Apogee Therapeutics Reports Positive Phase 1b Trial Results for APG808 in Asthma, Highlighting Durable FeNO Suppression and Potential for Extended Dosing Intervals - Nasdaq
Insider Sell: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) Projected to Post Quarterly Earnings on Monday - Defense World
Apogee Therapeutics chief medical officer sells shares totaling $97,418 By Investing.com - Investing.com Nigeria
Apogee Therapeutics chief medical officer sells shares totaling $97,418 - Investing.com Australia
APGE August 15th Options Begin Trading - Nasdaq
Stifel maintains $95 target on Apogee Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains $95 target on Apogee Therapeutics stock - Investing.com Australia
(APGE) On The My Stocks Page - news.stocktradersdaily.com
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade - Yahoo Finance
Apogee Therapeutics, Inc. (NASDAQ:APGE) Holdings Lowered by Invesco Ltd. - Defense World
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference - marketscreener.com
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference - GlobeNewswire Inc.
Wells Fargo & Company MN Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
JPMorgan Chase & Co. Has $1.69 Million Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):